Compositions for and methods of treating and preventing targeting tumor associated carbohydrate antigens

Compositions useful to induce anti-TACA immune response and kits comprising the same and methods of using the compositions to treat and prevent cancer are disclosed. Isolated human antibodies which bind to a carbohydrate mimetic peptide and methods of making the same and using the same to treat and prevent cancer are disclosed. Isolated human NK cells useful to kill tumor cells, and isolated human dendritic cells, and methods of making the same and using the same to treat and prevent cancer are disclosed.

ABSTRACT

Compositions useful to induce anti-TACA immune response and kits comprising the same and methods of using the compositions to treat and prevent cancer are disclosed. Isolated human antibodies which bind to a carbohydrate mimetic peptide and methods of making the same and using the same to treat and prevent cancer are disclosed. Isolated human NK cells useful to kill tumor cells, and isolated human dendritic cells, and methods of making the same and using the same to treat and prevent cancer are disclosed.

CLAIMS

1. A method of treating a human who has been diagnosed as having breast cancer, wherein the breast cancer is selected from the group consisting of i) triple negative breast cancer and ii) breast cancer that is HER2 positive, the method comprising administering to said human a composition comprising a compound having the structure of Formula 1:

Trp-Arg-Tyr-Thr-Ala-Pro-Val-His-Leu-Gly-Asp-Gly-dAla-Lys-CHAla-Val-Ala-Ala-Trp-Thr-Leu-Lys-Ala-Ala-dAla-NH2   Formula 1 wherein Ala13 and Ala25 are each D amino acids shown as dALa, and Ala at position 15 is cyclohexylalanine, a modified L configuration Alanine shown as CHAla.

PATENT INFORMATION


Interested in this Technology?

The technologies listed here are available for licensing or for developmental partnership.
Please contact us if you have any questions, or if you would like further information on these or other upcoming BioVentures technologies.

Contact